Genetic Technologies Statistics
Total Valuation
GENE has a market cap or net worth of $3.78 million. The enterprise value is $3.67 million.
Important Dates
The next estimated earnings date is Friday, December 13, 2024, before market open.
| Earnings Date | Dec 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GENE has 145.42 million shares outstanding. The number of shares has increased by 30.42% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 145.42M |
| Shares Change (YoY) | +30.42% |
| Shares Change (QoQ) | +29.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 27.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.48.
| Current Ratio | 0.88 |
| Quick Ratio | 0.75 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -205.22 |
Financial Efficiency
Return on equity (ROE) is -184.98% and return on invested capital (ROIC) is -91.95%.
| Return on Equity (ROE) | -184.98% |
| Return on Assets (ROA) | -62.93% |
| Return on Capital (ROIC) | -91.95% |
| Revenue Per Employee | $117,340 |
| Profits Per Employee | -$145,780 |
| Employee Count | 55 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 14.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.66% in the last 52 weeks. The beta is 0.48, so GENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -77.66% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 46.57 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | 25,845 |
| Short Previous Month | 25,845 |
| Short % of Shares Out | 0.56% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 15.67 |
Income Statement
In the last 12 months, GENE had revenue of $6.45 million and -$8.02 million in losses. Loss per share was -$0.06.
| Revenue | 6.45M |
| Gross Profit | 3.94M |
| Operating Income | -7.07M |
| Pretax Income | -8.41M |
| Net Income | -8.02M |
| EBITDA | -6.91M |
| EBIT | -7.07M |
| Loss Per Share | -$0.06 |
Full Income StatementBalance Sheet
The company has $693,487 in cash and $583,926 in debt, giving a net cash position of $109,560 or $0.00 per share.
| Cash & Cash Equivalents | 693,487 |
| Total Debt | 583,926 |
| Net Cash | 109,560 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 1.22M |
| Book Value Per Share | 0.01 |
| Working Capital | -333,659 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.46 million and capital expenditures -$21,996, giving a free cash flow of -$6.29 million.
| Operating Cash Flow | -6.46M |
| Capital Expenditures | -21,996 |
| Free Cash Flow | -6.29M |
| FCF Per Share | -$0.04 |
Full Cash Flow StatementMargins
Gross margin is 61.12%, with operating and profit margins of -109.52% and -124.24%.
| Gross Margin | 61.12% |
| Operating Margin | -109.52% |
| Pretax Margin | -124.24% |
| Profit Margin | -124.24% |
| EBITDA Margin | -107.07% |
| EBIT Margin | -109.52% |
| FCF Margin | -87.29% |